|9 Months Ended|
Sep. 30, 2022
|INTANGIBLE ASSETS [Abstract]|
Intangible assets at September 30, 2022 and December 31, 2021 consist of the following:
All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.5 million for the nine months ended September 30, 2022 and 2021 and $0.2 million for the three months ended September 30, 2022 and 2021. Estimated future aggregate amortization expense is expected to be as follows:
The entire disclosure for all or part of the information related to intangible assets.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef